Research programme: exportin 1-mediated nuclear export inhibitors - Karyopharm Therapeutics

Drug Profile

Research programme: exportin 1-mediated nuclear export inhibitors - Karyopharm Therapeutics

Alternative Names: CRM1-mediated nuclear export inhibitors - Karyopharm; KPT-185; KPT-350; KPT-SINE; SINE™ compounds; XPO1-mediated nuclear export inhibitors - Karyopharm

Latest Information Update: 09 Aug 2016

Price : $50

At a glance

  • Originator Karyopharm Therapeutics
  • Developer Icahn School of Medicine at Mount Sinai; Karyopharm Therapeutics
  • Class Small molecules
  • Mechanism of Action Exportin-1 protein inhibitors; Nuclear export inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders; HIV infections; Inflammation; Influenza virus infections; Wounds

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Amyotrophic lateral sclerosis; Autoimmune disorders; Brain injuries; Cancer; HIV infections; Inflammation; Multiple sclerosis; Skin disorders; Wounds

Most Recent Events

  • 04 Aug 2016 KPT 350 is available for licensing for development and commercialisation
  • 20 Apr 2016 Pharmacodynamics data from preclinical studies presented at the Annual Meeting of the American Academy of Neurology (AAN-2016)
  • 15 Sep 2015 Pharmacodynamics data from a preclinical trial in traumatic brain injury released by Karyopharm
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top